Literature DB >> 33626424

Prevalence and predictors of breast cancer-related arm lymphedema over a 10-year period in postoperative breast cancer patients: A cross-sectional study.

Yan-Fei Liu1, Jun-E Liu2, Yim Wah Mak3, Yi Zhu4, Hui Qiu5, Li-Hui Liu6, Shen-Shen Yang5, Shao-Hua Chen5.   

Abstract

PURPOSE: Breast cancer (BC) survivors have a lifelong risk of developing lymphedema. This study investigated the prevalence of BC-related arm lymphedema among Chinese BC survivors diagnosed in the last 10 years and examined the demographic and clinical variables as well as lifestyle factors associated with lymphedema status.
METHODS: In this cross-sectional study, women with BC (N = 866) who had been diagnosed and followed up in the previous 10 years were recruited from the outpatient clinic of 4 general hospitals and one cancer association in China between August 2018 and October 2019. Lymphedema status was determined using the Norman telephone questionnaire as the patient-reported occurrence of hand/lower arm/upper arm swelling. Multiple logistic regression was used to identify risk factors for lymphedema.
RESULTS: The median time from BC diagnosis was 4.0 years (interquartile range, 2.0-5.0 years). 81.4% of the patients had undergone mastectomy. The prevalence of arm lymphedema among BC survivors was 49.0%. Age ≥50 years, monthly income <3000 RMB, modified radical mastectomy, postsurgical wound infection, chemotherapy, and radiotherapy were associated with an increased risk of BC-related arm lymphedema, whereas exercise of the affected arm, engagement in active physical activity, and timely reporting of symptoms of infection to a physician decreased the risk (P < 0.05).
CONCLUSIONS: Arm lymphedema is a common complication for postoperative BC survivors within 10 years. It is essential to identify patients at risk of lymphedema based on demographic, clinical, and lifestyle factors and implement interventions targeting modifiable lifestyle behaviors-eg, active physical activity during the postoperative period.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Breast cancer; Lymphedema; Prevalence; Risk factor

Mesh:

Year:  2021        PMID: 33626424     DOI: 10.1016/j.ejon.2021.101909

Source DB:  PubMed          Journal:  Eur J Oncol Nurs        ISSN: 1462-3889            Impact factor:   2.398


  3 in total

Review 1.  Noninvasive Measurements of Breast Cancer-Related Lymphedema.

Authors:  Harvey N Mayrovitz
Journal:  Cureus       Date:  2021-11-22

2.  Bioelectrical impedance analysis for early screening of upper limb subclinical lymphedema: A case-control study.

Authors:  Linli Zhuang; Huaying Chen; Xuemei Zheng; Shaoyong Wu; Youhui Yu; Lu Lan; Liang Xu; Jumei Xu; Hongying Fan
Journal:  PLoS One       Date:  2022-09-19       Impact factor: 3.752

3.  Comprehensive analysis reveals potential hub genes and therapeutic drugs in an acquired lymphedema model.

Authors:  Chaoran Qiu; Jiemei Chen; Hui Huang; Zhiquan Lin; Yiwen Zhang; Chunbang Liao; Mei Yang; Yuting Qu; Shengchao Huang; Weiwen Li; Xiaoping Li
Journal:  Gland Surg       Date:  2022-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.